Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration.

Key Points

• This research aims to explore the mechanisms by which CBD and CBG benefit steatotic liver disease.
• Investigated effects of CBD and CBG on hepatic functions.
• Assessed mechanisms related to phosphocreatine buffering and lysosomal activity.
• Identified endocannabinoid system-independent actions of CBD and CBG.
• Demonstrated improvements in hepatic energy buffering and lysosomal restoration.